Mizuho Securities analyst Graig Suvannavejh has maintained their neutral stance on APLS stock, giving a Hold rating on January 14.Stay Ahead ...

The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and ...

CEO Bill Sibold hailed 2024 as a "transformational year" for Madrigal Pharmaceuticals, but Wall Street isn't as enthusiastic ...

A Midtown-based therapeutics company hopes to tap the growing market of anti-aging drugs with a suite of pharmaceutical ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

Will fund a pilot study to analyze longitudinal plasma samples covering a period of up to 10 years.

Spanish drugmaker Grifols has been awarded a $21 million grant from the Michael J Fox Foundation to support a pilot study to ...

Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms ...

U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding ...

U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding more transparency from the embattled pharmaceutical company Grifols ...

European equities traded in the US as American depositary receipts were trending lower late Friday morning, declining 0.43% to 1,306.41 on the S&P Europe Select ADR Index. From continental Europe, the ...